- Home
- ASM vs VTYX Comparison
ASM vs VTYX Comparison
Compare ASM & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | VTYX |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 990.9M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASM | VTYX |
|---|---|---|
| Price | $7.84 | $13.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | $8.18 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 4.4M | 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.91 | N/A |
| Revenue Next Year | $104.71 | N/A |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $0.90 |
| 52 Week High | $11.99 | $15.34 |
Technical Indicators
Market Signals| Indicator | ASM | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 72.58 |
| Support Level | $3.70 | $13.89 |
| Resistance Level | $11.99 | $14.07 |
| Average True Range (ATR) | 0.63 | 0.03 |
| MACD | -0.25 | -0.11 |
| Stochastic Oscillator | 12.81 | 88.89 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.